Đang chuẩn bị liên kết để tải về tài liệu:
A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Previous studies have reported that neoadjuvant chemoradiotherapy can downstage the advanced gastric cancer. However, no studies are available on the application of hypo-radiotherapy to neoadjuvant radiotherapy. | A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

TÀI LIỆU LIÊN QUAN

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases

A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: A study protocol

Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: A prospective, phase II, multicentre, single-arm study

A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: A prospective phase I subanalysis

Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: A prospective randomized phase III study

Effcacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial